About Ophthotech Corporation
Ophthotech Corporation is a biopharmaceutical company. The Company specializes in the development of therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (AMD). Its advanced product candidate is Fovista, which is for use in combination with anti-vascular endothelial growth factor (VEGF) drugs. It is also developing its product candidate Zimura for the treatment of patients with geographic atrophy, a form of dry AMD, in combination with VEGF therapy for the treatment of polypoidal choroidal vasculopathy (PCV). Fovista is being tested in Phase III clinical development. In addition, it has initiated additional clinical trials to evaluate the potential additional benefits of Fovista administered in combination with anti-VEGF drugs in wet AMD patients, known as Fovista Expansion Studies. Zimura has completed a small, multicenter, uncontrolled, open label Phase I/IIa clinical trial.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: OPHT
- Previous Close: $4.26
- 50 Day Moving Average: $4.63
- 200 Day Moving Average: $30.16
- 52-Week Range: $4.19 - $65.96
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.12
- P/E Growth: 0.00
- Market Cap: $152.07M
- Outstanding Shares: 35,697,000
- Beta: 1.85
- Net Margins: -323.19%
- Return on Equity: -916.07%
- Return on Assets: -41.63%
Companies Related to Ophthotech Corporation:
- Current Ratio: 6.07%
- Quick Ratio: 6.07%
What is Ophthotech Corporation's stock symbol?
Ophthotech Corporation trades on the NASDAQ under the ticker symbol "OPHT."
Where is Ophthotech Corporation's stock going? Where will Ophthotech Corporation's stock price be in 2017?
12 equities research analysts have issued 1 year target prices for Ophthotech Corporation's shares. Their forecasts range from $11.00 to $92.00. On average, they anticipate Ophthotech Corporation's share price to reach $59.11 in the next year.
When will Ophthotech Corporation announce their earnings?
Ophthotech Corporation is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.
Who owns Ophthotech Corporation stock?
Ophthotech Corporation's stock is owned by a number of of institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (6.42%), State Street Corp (4.36%), Tourbillon Capital Partners L.P. (3.81%), Bogle Investment Management L P DE (3.58%), Fiera Capital Corp (2.54%) and Guggenheim Capital LLC (1.17%). Company insiders that own Ophthotech Corporation stock include A/S Novo, Axel Bolte, Barbara A Wood, David R Guyer, Glenn Sblendorio, Henric Bjorn Bjarke, Nicholas Galakatos and Samir Chandrakant Patel.
Who bought Ophthotech Corporation stock? Who is buying Ophthotech Corporation stock?
Ophthotech Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Tourbillon Capital Partners L.P., Bogle Investment Management L P DE, State Street Corp, Guggenheim Capital LLC, Numeric Investors LLC, Quinn Opportunity Partners LLC and Fiera Capital Corp.
How do I buy Ophthotech Corporation stock?
Shares of Ophthotech Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Ophthotech Corporation stock cost?
One share of Ophthotech Corporation stock can currently be purchased for approximately $4.26.